在 STAMPEDE 试验平台中，将二甲双胍重新用作前列腺癌的治疗药物。
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
机构信息
Department of Oncology/Haematology, Kantonsspital, St. Gallen, Switzerland.
MRC Clinical Trials Unit, University College London, London, UK.
出版信息
Eur Urol. 2016 Dec;70(6):906-908. doi: 10.1016/j.eururo.2016.07.015. Epub 2016 Jul 19.
Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.
二甲双胍是一种安全、耐受良好、价格低廉的治疗方法，可与当前前列腺癌的标准治疗方法联合使用。它的使用可能减轻去势治疗的有害副作用，并发挥额外的抗癌作用。它将于 2016 年夏季纳入 STAMPEDE 试验平台。这将检验二甲双胍作为一种重新用于治疗初诊时患有高危局部晚期或转移性前列腺癌的男性的真正用途。
Zotero 插件